Latest News & Features
Americas
The US Food and Drug Administration, along with international police organization Interpol, has targeted more than 1,000 websites that sell fake, unapproved medicines and medical devices. 24 June 2015
Americas
The US Court of Appeals for the Federal Circuit has affirmed a lower court ruling which said that a reissue patent covering Pfizer’s arthritis drug Celebrex was invalid for obviousness-type double patenting. 24 June 2015
Asia-Pacific
China’s State Intellectual Property Office has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group. 23 June 2015
Americas
A US appeals court has for the second time invalidated a patent covering pharmaceutical company Teva’s multiple sclerosis drug Copaxone. 22 June 2015
Big Pharma
Law firm Pinsent Masons has expanded its Munich office with the hire of Marc Holtorf as partner. 22 June 2015
Americas
US law firm Honigman Miller Schwartz and Cohn has hired two intellectual property lawyers as partners. 19 June 2015
Americas
Recent patent decisions in the life sciences sector are leading biotechnology companies to seek protection for their innovations by using alternatives to patents, with trade secrets the most viable, the BIO International Convention has heard. 18 June 2015
Americas
On day three of the BIO International Convention, LSIPR spoke to Kevin Noonan and Donald Zuhn, partners at law firm McDonnell Boehnen Hulbert & Berghoff and authors of the Patent Docs blog, about the possible impact of the Federal Circuit’s Ariosa v Sequenom decision on the life sciences industry. 18 June 2015
Americas
The question of whether using a known drug for treating a known disease, but in a distinct sub-population of patients, can constitute a patentable new invention is key to the development of personalised medicine, says Stephen Smith of Potter Clarkson. 18 June 2015
Americas
Scott Kamholz, a former judge at the Patent Trial and Appeal Board, recently returned to law firm Foley Hoag as partner. LSIPR spoke to him at this year’s BIO International Convention, where he explained why the inter-partes review is not a “death squad” for patents. 18 June 2015